The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Orforglipron significantly reduced HbA1c levels by 1.3% (3mg), 1.6% (12mg), and 1.5% (36mg) compared with 0.1% in the placebo arm. Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1 ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

The study, published Friday during the 32nd European Congress on Obesity in Spain, also found these GLP-1 drugs were more effective than a drug called ... in alcohol use to explore a possible ...

Weight Loss Drug Users Are Giving Up Their Vices This new study was prospective, meaning the researchers proactively tracked how people’s alcohol use changed after starting GLP-1 therapy (many ...

The study tested the drug as a monotherapy ... which Lilly said indicates that patients could lose more with continued use of the drug. Like other GLP-1 drugs, the most common adverse effects ...

Early animal studies have indicated that GLP-1 drugs can help cut alcohol cravings, but studies involving humans are only starting to emerge, researchers said. For this study, researchers tracked ...

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

The observational, real-life retrospective cohort study found that in adults with obesity and type 2 diabetes but no prior heart disease, glucagon-like peptide-1 receptor agonists (GLP-1RAs ...

The real-world study involved ... by nalmefene, a drug used to treat alcohol use disorder in Europe, notes Professor le Roux. He adds: “The exact mechanism of how GLP-1 analogues reduce alcohol ...